This is a past event. Registration is closed. View other OBN events.
Yusuf Ali
Client Director of Partners&Yusuf has over 12 years of experience within the insurance and financial services industry and previously worked for an insurance partner that led the way in technical and specialist areas of wellbeing, health and protection advice. Yusuf’s role at Partners& involves working closely with science and technology sector, particularly when it comes to supporting businesses seeking funding and helping them be “investment ready”.
Kat Arney
Chief Creative Officer at First Create The Media LtdDr Kat Arney, Chief Creative Officer, First Create The Media
Kat is a multi award-winning science writer and broadcaster, and is the founder and Chief Creative officer of First Create The Media - a communications strategy and content agency specialising in the life sciences. We make world-changing bioscience innovations become reality by helping the brightest pioneers and initiatives grab the attention of the people who can make it happen.
Mitasha Bharadwaj
Patent Specialist at Marks & ClerkMitasha has a PhD in Biophysics from ETH Zurich, Switzerland, and a postdoc from TU Delft, Netherlands, which led her on an inspiring entrepreneurial journey in the med-tech space. With over a decade of research experience in life sciences, she is a passionate advocate for bioentrepreneurship and IP rights.
Jordy Breuker
Associate Capital Advisory at F.INSTITUTEJordy joined the Capital Advisory team at F.INSTITUTE in 2023 and brings a wealth of financial and life sciences experience into play. He moved into finance directly after finishing his Biomedical Sciences degree, starting his career at Kempen & Co, a life sciences-focused investment bank, working on IPO and other public market transactions, as well as managing M&A processes. Following Kempen he helped set up and lead the biotech team at NLC Health Ventures, a studio focused on healthtech, pulling research out of academia and building companies around that technology. His current focus is on fractional CFO and fundraising projects.
Matthew Clark
Cyber Director of Partners& LtdMatthew has worked with life science businesses for over 20 years, helping them to arrange intelligent insurance and risk management controls. As Cyber Director with Partners&, the next-generation risk advisory business, Matthew helps companies in all sectors and of all sizes to understand, prepare for and respond to cyber-attacks.
Lorna Cuddon
Managing Director of Zyme Communications LtdLorna founded Zyme Communications in 2010, and has grown the business into a successful agency with offices in Cambridge and Manchester in the UK, providing strategic and specialist advice to life science and medtech organisations globally. Focused on supporting companies to raise their profile, build corporate value, and generate commercial interest, Zyme’s portfolio extends from early stage start-ups to industry giants, across the US, Europe and Asia.
With more than 20 years’ experience in PR and marketing in the life science sector, Lorna was previously Associate Partner at international communications agency Instinctif Partners, where she was responsible for the company’s largest portfolio of clients. She also gained in-house experience in marketing communications roles at science focused companies. Lorna has experience advising companies such as Bio-Rad, GE Healthcare, Promega, Revvity, Abcam, Cancer Research Technology, Illumina, Life Arc and many more.
Lorna has a degree in Natural Sciences, majoring in Biology and Biochemistry and is an Associate member of the Chartered Institute of Marketing.
Richard Fox
Assistant Director Business Engagement & Research Impact of Precision Health Technologies AcceleratorRichard is the Assistant Director for Business Engagement and Research Impact at University of Birmingham, supporting the College of Medicine and Health. With over a decades experience working at the intersection between academia, industry and public sector organisations, Richard has built and led successful teams supporting the translation and commercialisation of research in the engineering and life science sectors, working with key regional, national and international partners to develop academic-industry links and strategic business partnerships. Through Birmingham Health Partners, Richard also supports the regional objectives of positioning the NHS, academia and industry to align research excellence, clinical need and the ability for industry to translate into products that provide patient benefit.
Michael Green
Co-founder & Strategy Director of Luna 9Michael is the founder of Luna 9 – a creative agency accelerating commercial traction for innovative organisations by explaining what they do and why it matters. His passion for clear storytelling and impactful design has helped scaling companies from across the biotech sector to perfect their pitch decks, messaging, and brand identity, resulting in over £100m raised in investment in the last 12 months alone.
Manisha Kulkarni
Director of Science & Technology at Bulb LaboratoriesManisha, an Organic Chemist by background, has extensive experience in interdisciplinary drug discovery and development research prior to developing strong expertise in high-tech R&D facility design.
At Bulb, her contributions encompass assessing building suitability for scientific purposes and conceptualizing state-of-the-art R&D laboratories(CL1-3), incubator spaces, and advanced manufacturing facilities (GMP, Cleanrooms) by maintaining an unwavering focus on clients' scientific needs.
Manisha strategically advises on market penetration in the science and technology sectors through networking, thought leadership and trends analysis.
David Lang
Senior Associate at Marks & ClerkDavid practises in patent matters in three main areas: healthcare, advanced materials, and food technology. David drafts, files and prosecutes patent applications worldwide, advises on freedom to operate, and is experienced in opposition and appeal matters at the European Patent Office, litigation in the UK, and supplementary protection certificates (SPCs) in the UK, EU and beyond.
In the healthcare sector, David routinely advises on inventions relating to new chemical entities and formulations, new indications for existing medicines, and medical devices. David has particular experience in antiviral medicines and wearables.
Sergio Lentojo Mozo
Director of Manufacturing at Quantum SolutionsSergio Lentijo Mozo is the Director of Manufacturing at Quantum Solutions. Sergio obtained his MSc in 2004 and his Ph.D. in Chemistry (with a focus on Organometallic Chemistry) from the University of Valladolid in Spain in 2009. Before joining Quantum Solutions, he pursued a career as a researcher in the field of nanochemistry at various international research centers, including the LPCNO institute at INSA Toulouse (France) and KAUST in the BESE department (Saudi Arabia). Sergio possesses extensive expertise in nanoparticles manufacturing operations across various domains.
Wenjie Li
Vice President of the CMC Unit at MedicilonDr. Wenjie Li, holds a Bachelor's degree from Peking University and Masters and Ph.D. degrees in Organic Chemistry from the University of Pittsburgh.
With nearly three decades in pharmaceutical R&D management, Dr. Wenjie Li has deep expertise in drug development, including CMC services and CRO/CDMO management, accumulating rich experience and profound knowledge. He is familiar with all the various stages of new drug and generic drug process development, manufacturing transfer, process validation, commercial production, and application. He is able to accurately control every aspect of drug R&D processes. Additionally, Dr. Li has outstanding academic achievements, publishing over 20 papers in international journals and receiving nearly 20 invention patents, contributing valuable insights to the industry.
Before joining Medicilon, Dr. Wenjie Li was engaged in innovative drug and generic drug process R&D and CMC management at Merck Research Laboratories (USA), Boehringer Ingelheim Pharmaceuticals, Sichuan Kelun Pharmaceutical Research Institute (China), and TransThera Bioscience Co., receiving multiple corporate awards for his outstanding performance and contributions.
Stewart Liberman
Director of Business Development, EMEA Biotech at ThermoFisher ScientificStewart Liberman is a highly accomplished professional with 20+ years of experience in clinical trials and business development. Currently serving as the Director of Business Development, EMEA Biotech at Thermo Fisher Scientific, his expertise in navigating the biotech industry and fostering successful collaborations is widely recognized. With a track record of excellence in managing diverse accounts and driving business growth, Stewart is a sought-after expert in the field. His passion for innovation and deep industry knowledge is evident in his contributions to industry publications and events, globally
Russell Oakley
Associate Director Business Development of CK Associates Group
Adam Pickford
Co-Founder and Director of HighlightpeopleWe set up Highlight People as we love to see businesses winning by getting the best from their employees.
I bring my People Development expertise and passion to understand your business and identify the best ways we can help you. This often includes a range of HR, learning and engagement interventions which enable people to develop and their performance to flourish.
Christian Vecchione
Founder and Managing Director of Benedicts Consultant SurveyorsChristian is the Founder and Managing Director at Oxford-based commercial property advisors, Benedicts Consultant Surveyors.
Christian established Benedicts Consultant Surveyors in 1997 and, since then, has been providing a full range of commercial property services to corporate and private clients.
He has long experience working with all asset classes, both as advisor and principal but has built up a particular specialism in the science and technology sector, acting as letting agent at Oxford Technology Park since inception and representing a range of occupier clients engaged in the Life Science, Materials Science and Nuclear industries.
Alex Wilshaw
Associate Director of Ironstone Asset ManagementAlex started his property career with Aston Rose, a multi-disciplinary firm of chartered surveyors. Roles in property management, agency, professional work and investment, accumulated a wealth of sector experience and contacts before joining Tilstone Partners (investment advisor to Warehouse REIT). Over five years, he progressed from an asset manager to associate director, primarily responsible for identifying and driving value across a UK focused industrial and logistics portfolio, valued in excess of £1Bn. Transactional highlights included several high profile multi-let and portfolio purchases.
Having lived in Oxford, London and being within easy reach of Cambridge, Alex is well positioned to apply his real estate capabilities to identify and capitalise on opportunities throughout the Golden Triangle Life Sciences market.
In addition to a BA (Hons) degree from the University of Birmingham, Alex holds a postgraduate diploma in education, one in surveying as well as being a qualified chartered surveyor. He is a member of several high-profile networking groups including the Investment Property Forum, the UK Real Estate investment and infrastructure Forum and Royal Institute of Chartered Surveyors.